| Not Yet Recruiting | Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Cl NCT07433088 | Streetlab | N/A |
| Not Yet Recruiting | Wide Field OCTA in Ocular Diseases NCT07298174 | IRCCS San Raffaele | — |
| Recruiting | SGLT2 Inhibitors in Geographic Atrophy NCT07174687 | Washington University School of Medicine | Phase 2 |
| Recruiting | A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic NCT07215234 | Sanofi | Phase 1 / Phase 2 |
| Enrolling By Invitation | Real-time Acoustic Biofeedback for Enhancing Fixation Stability: A Proof-of-concept Study to Improve Ophthalmi NCT07529041 | University Medical Center Goettingen | N/A |
| Recruiting | Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants NCT07160179 | AbbVie | Phase 1 / Phase 2 |
| Recruiting | A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy) NCT06557460 | Regenerative Patch Technologies, LLC | Phase 2 |
| Recruiting | A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity NCT06961370 | Hoffmann-La Roche | Phase 1 |
| Recruiting | A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age- NCT06970665 | Astellas Pharma Inc | Phase 4 |
| Not Yet Recruiting | A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geograp NCT07029945 | Biojiva LLC | Phase 1 / Phase 2 |
| Recruiting | Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With NCT06351657 | Medical University of Vienna | — |
| Active Not Recruiting | A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degenerati NCT06769048 | Boehringer Ingelheim | Phase 2 |
| Recruiting | A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT NCT06805474 | Nanoscope Therapeutics Inc. | — |
| Recruiting | A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic NCT06779773 | Astellas Pharma Global Development, Inc. | — |
| Active Not Recruiting | A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) NCT06722157 | Boehringer Ingelheim | Phase 2 |
| Completed | The GA in HSI Study NCT06860568 | Optina Diagnostics Inc. | — |
| Recruiting | A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrop NCT06635148 | Janssen Research & Development, LLC | Phase 2 |
| Active Not Recruiting | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007 NCT06510816 | Annexon, Inc. | Phase 3 |
| Completed | Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration NCT07428798 | Marmara University Pendik Training and Research Hospital | N/A |
| Recruiting | Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Deg NCT06394232 | Eyestem Research Pvt. Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy NCT06164587 | Michelle Abou-Jaoude | Phase 1 / Phase 2 |
| Completed | Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration NCT06381596 | University of Wisconsin, Madison | N/A |
| Completed | COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy NCT05961332 | University of Wisconsin, Madison | N/A |
| Completed | A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-rel NCT06006585 | Boehringer Ingelheim | Phase 1 |
| Active Not Recruiting | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerabilit NCT06161584 | Apellis Pharmaceuticals, Inc. | — |
| Unknown | A Study of the SING IMT in an Israeli Cohort NCT05941273 | VisionCare, Inc. | N/A |
| Active Not Recruiting | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atro NCT05949593 | Belite Bio, Inc | Phase 3 |
| Recruiting | Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration NCT06087458 | Perceive Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Patients With Geographic Atrophy and Their Patient Journey in the United States (US) NCT05891275 | Boehringer Ingelheim | — |
| Recruiting | A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participant NCT05626114 | Genentech, Inc. | Phase 2 |
| Completed | A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Ge NCT05811351 | Janssen Research & Development, LLC | Phase 2 |
| Active Not Recruiting | Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy NCT06018558 | Ocugen | Phase 1 / Phase 2 |
| Active Not Recruiting | Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study NCT05797896 | Complement Therapeutics | — |
| Active Not Recruiting | Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration NCT05380492 | Perceive Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy NCT05536297 | Astellas Pharma Global Development, Inc. | Phase 3 |
| Completed | Geographic Atrophy Long-Terms Outcomes Study NCT06499571 | Apellis Pharmaceuticals, Inc. | — |
| Recruiting | Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD NCT05438732 | VisionCare, Inc. | N/A |
| Terminated | A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration NCT05019521 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Withdrawn | Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA) NCT04358471 | Hemera Biosciences | Phase 2 |
| Completed | ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degenerati NCT04744662 | ONL Therapeutics | Phase 1 |
| Completed | Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study NCT05963646 | Institute of Molecular and Clinical Ophthalmology Basel | — |
| Completed | A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic NCT04656561 | Annexon, Inc. | Phase 2 |
| Recruiting | Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression NCT04739319 | Center for Eye Research Australia | — |
| Completed | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections o NCT04615325 | Hoffmann-La Roche | Phase 1 |
| Unknown | Oral Postbiotics in Patients With Macular Atrophy NCT05391074 | Institut de la Macula y la Retina | N/A |
| Active Not Recruiting | Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD NCT04676854 | Science Corporation | N/A |
| Terminated | A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geograp NCT04607148 | Genentech, Inc. | Phase 2 |
| Recruiting | Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic NCT04339764 | National Eye Institute (NEI) | Phase 1 / Phase 2 |
| Terminated | A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration NCT04643886 | Gemini Therapeutics, Inc. | Phase 2 |
| Completed | A Study of NGM621 in Participants With Geographic Atrophy NCT04465955 | NGM Biopharmaceuticals, Inc | Phase 2 |
| Completed | A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) NCT04435366 | IVERIC bio, Inc. | Phase 3 |
| Completed | First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry NCT04246866 | Gemini Therapeutics, Inc. | Phase 1 |
| Completed | Study of NGM621 in Participants With Geographic Atrophy NCT04014777 | NGM Biopharmaceuticals, Inc | Phase 1 |
| Terminated | A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geogra NCT03972709 | Genentech, Inc. | Phase 2 |
| Completed | Phase 2/3 Study of ALK-001 in Geographic Atrophy NCT03845582 | Alkeus Pharmaceuticals, Inc. | Phase 2 / Phase 3 |
| Completed | GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geo NCT03815825 | Ionis Pharmaceuticals, Inc. | Phase 2 |
| Terminated | GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD) NCT03894020 | Gyroscope Therapeutics Limited | — |
| Terminated | FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects NCT03846193 | Gyroscope Therapeutics Limited | Phase 1 / Phase 2 |
| Completed | Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy NCT03777332 | Apellis Pharmaceuticals, Inc. | Phase 1 |
| Completed | Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With G NCT03525600 | Apellis Pharmaceuticals, Inc. | Phase 3 |
| Completed | A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With NCT03525613 | Apellis Pharmaceuticals, Inc. | Phase 3 |
| Withdrawn | Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographi NCT02895815 | Janssen Pharmaceutical K.K. | Phase 2 |
| Withdrawn | Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary NCT03446144 | Ionis Pharmaceuticals, Inc. | Phase 2 |
| Completed | Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Relat NCT03295877 | Genentech, Inc. | Phase 1 |
| Terminated | Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Se NCT02745119 | Hoffmann-La Roche | Phase 3 |
| Completed | Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD NCT02800356 | Ospedale San Raffaele | N/A |
| Completed | Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD NCT02684578 | University of California, San Francisco | Phase 2 |
| Unknown | Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD NCT02590692 | Regenerative Patch Technologies, LLC | Phase 1 / Phase 2 |
| Completed | Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration NCT02686658 | IVERIC bio, Inc. | Phase 2 / Phase 3 |
| Completed | A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants NCT02659098 | Janssen Research & Development, LLC | Phase 2 |
| Completed | CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atro NCT02515942 | Alcon Research | Phase 2 |
| Completed | Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy NCT02503332 | Apellis Pharmaceuticals, Inc. | Phase 2 |
| Terminated | A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degene NCT02479386 | Hoffmann-La Roche | — |
| Completed | A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participan NCT02288559 | Genentech, Inc. | Phase 2 |
| Terminated | A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degene NCT02399072 | Hoffmann-La Roche | — |
| Completed | Evaluating the Relationship Between Function and Structure in ARCHER II-like Population Using Data From a Natu NCT07424235 | IRCCS Ospedale San Raffaele | — |
| Unknown | Geographic Atrophy and Intravitreal Ranibizumab Injections NCT02372916 | University Health Network, Toronto | — |
| Terminated | A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geo NCT02247531 | Hoffmann-La Roche | Phase 3 |
| Completed | Sparing of the Fovea in Geographic Atrophy Progression NCT02332343 | University Hospital, Bonn | — |
| Terminated | A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geo NCT02247479 | Hoffmann-La Roche | Phase 3 |
| Terminated | A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related NCT02087085 | Allergan | Phase 2 |
| Terminated | Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atroph NCT02137915 | StemCells, Inc. | — |
| Completed | Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry NCT02130531 | Kubota Vision Inc. | Phase 1 |
| Recruiting | High Resolution Retinal Imaging NCT01866371 | University of Pennsylvania | — |
| Completed | Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride NCT01802866 | Kubota Vision Inc. | Phase 2 / Phase 3 |
| Completed | Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) NCT01782989 | Paul Yates, MD, PhD | Phase 2 / Phase 3 |
| Completed | Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO NCT01692938 | Optos, PLC | — |
| Completed | Micropulse Laser for Geographic Atrophy NCT01799564 | Institut de la Macula y la Retina | N/A |
| Terminated | A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Assoc NCT01603043 | Alcon Research | Phase 2 |
| Terminated | An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy NCT01602120 | Genentech, Inc. | Phase 2 |
| Terminated | Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy NCT01675947 | National Eye Institute (NEI) | Phase 2 |
| Completed | Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) NCT01527500 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Sirolimus for Advanced Age-Related Macular Degeneration NCT01445548 | National Eye Institute (NEI) | Phase 1 / Phase 2 |
| Withdrawn | A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy NCT01093170 | Mark Kleinman | Phase 1 |
| Completed | A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Mon NCT01229215 | Genentech, Inc. | Phase 2 |
| Completed | Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE) NCT01272076 | Carl Zeiss Meditec, Inc. | — |
| Completed | Evolution and Risk Factors Associated With Geographic Atrophy Progression NCT01694095 | Institut de la Macula y la Retina | — |
| Completed | Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geograph NCT01002950 | Kubota Vision Inc. | Phase 2 |
| Completed | A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD45 NCT00973011 | Genentech, Inc. | Phase 1 |
| Terminated | Geographic Atrophy Treatment Evaluation NCT00890097 | Alcon Research | Phase 3 |
| Terminated | The Natural History of Geographic Atrophy Progression (GAP) Study NCT00599846 | Alcon Research | — |
| Completed | Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degenerati NCT00429936 | Sirion Therapeutics, Inc. | Phase 2 |
| Completed | OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration NCT00306488 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population NCT01666821 | Shanghai University of Traditional Chinese Medicine | — |